Denmark, Iceland, Austria, Estonia, Lithuania, Luxembourg, and Latvia have suspended the administration of AstraZeneca COVID-19 vaccines after an unconfirmed number of patients who have been inoculated developed blood clots.
The Danish Health Authority announced that they are suspending the use of the AstraZeneca coronavirus vaccine for 14 days after there were reports of “serious cases of blood clots among vaccinated people.”
The Danish Health Authority did not disclose how many patients had blood clots and did not specify if there was a direct link between the vaccine and the blood clots, “at the time being.”
In Austria, the national medicines regulator suspended the inoculations after four patients had blood clots while one person died from thromboses after receiving the vaccine 10 days before.
Another Austrian patient was diagnosed with pulmonary embolism after getting vaccinated but was reported to be recovering.
The European Medicines Agency (EMA) said there is currently no evidence that the vaccine caused the clotting, and that thrombosis was not reported to be a potential side effect of the vaccine.
Estonia, Lithuania, Luxembourg, and Latvia have also announced suspending the use of AstraZeneca while investigations are ongoing regarding the blood clot cases.
EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) would be in charge of investigating the cases.
AstraZeneca claimed that their vaccines were subjected to strict and rigorous quality checks and that there have been “no confirmed serious adverse events associated with the vaccine” so far.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.